Home > Boards > Stock Clubs > Market Trends and Strategies > $OLID GAINER$ BOARD

Cellceutix yearly progress

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
25 Kilos of Gold Member Profile
 
Followed By 27
Posts 1,080
Boards Moderated 0
Alias Born 08/30/06
160x600 placeholder
25 Kilos of Gold   Wednesday, 03/11/15 05:50:19 AM
Re: None
Post # of 1115 
Cellceutix yearly progress
2011
Q1 2011 Market Cap 36.58 MM

2012

Q1 2012 Market Cap 47.55 MM

October 8 2012 Initiates the Phase I D-F trials for Kevetrin

2013
Q1 2013 Market Cap 165.52 MM

June 3 2013 Presented poster ASCO Kevetrin
June 17 2013 Stability test for Purisol tablets
September 15 2013 Aquires Polymedix
October 2 2013 IND new Psoriasis drug Prurisol

2014
February 24 2014 Brilacidin ophthalmic and otitis formulations started
February 25 2014 First patients 2b ABSSI enrolled
March 19 2014 Seventh cohort for Kevetrin initiated
March 24 2014 Initiates clinical trials for Prurisol

Q1 2014 Market Cap 173.64

May 5 2014 Prurisol completes first cohort
June 16 2014 Eight cohort entering for Kevetrin
July 18 2014 Breakthrough formulation for Brilacidin
Aug 07 2014 Prurisol primary end point met
Sept 19 2014 IND filed Brilacidin OM
Oct 23 2014 IND Brilacidin OM becomes effective
Oct 31 2014 Positive Top Line data regarding Brilicidin phII b
December 10 2014 Brilacidin QIPD designation
December 22 2014 Psoriasis FDA aproves initiation phII


Q1 2015 Market Cap 400 +

Jan 05 2015 Brilacidin confidence intervals revealed
Jan 20 2015 Kevetrin 10th cohort commenced 450mg/m2
Jan 26 2015 Meeting lawyers for Nasdaq listing. New pre-IND for gastrointestinal decease. FDA meeting requested


De reir a cheile a thogtar na caisleain
Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences